Sun Pharma Q2 FY26 Results: 8.6% Revenue Growth, ₹31,180 Million Net Profit, and Strong R&D Momentum

Share With Your Friends

Mumbai, India: Sun Pharmaceutical Industries Limited, India’s largest and one of the world’s leading specialty generic pharmaceutical companies, announced its consolidated financial results for the second quarter ended September 30, 2025 (Q2 FY26).

The company showcased robust revenue growth, strong profitability, and consistent R&D investments, highlighting the strength of its diverse business model spanning formulations, APIs, and specialty medicines across more than 100 countries.

Contents

1 Financial Performance Overview
2 Segment-Wise Business Performance
3 Innovation and Research Focus
4 Management Commentary
5 Strategic Outlook
6 Investor and Market Insight
7 Conclusion
8 Related Posts

Financial Performance Overview

Sun Pharma reported consolidated net sales of ₹144,052 million, marking an 8.6% year-on-year growth. The company’s EBITDA stood at ₹45,271 million, up 14.9% YoY, translating to an EBITDA margin of 31.3% — a sign of strong operational efficiency.

Profit before tax rose to ₹41,676 million (up 15.8%), while net profit reached ₹31,180 million, a 2.6% increase compared to the same quarter last year.

For the first half of FY26, Sun Pharma’s revenue reached ₹281,913 million, reflecting 9.3% YoY growth, supported by consistent expansion in both India and international markets.

R&D expenditure stood at ₹7,827 million in Q2, accounting for 5.4% of sales, reinforcing Sun Pharma’s focus on innovation and development of differentiated products.

Segment-Wise Business Performance

India Formulations

The Indian formulations business, which remains Sun Pharma’s largest revenue driver, generated ₹47,348 million, showing 11% year-on-year growth.
The company continues to maintain its leadership in the Indian branded formulations market, improving its overall market share from 8.0% to 8.3% (MAT September 2025).
This growth was supported by new product launches (9 in Q2 and 15 in H1 FY26) and a strong focus on specialty therapies, chronic segments, and consumer healthcare.

US Formulations

Sun Pharma’s US business recorded sales of US$496 million, contributing 30.1% of consolidated revenues.
While the generic portfolio saw a mild decline, the company achieved a strategic milestone — the Innovative Medicines business in the US surpassed generics in revenue for the first time.
This reflects the company’s long-term strategy of reducing dependence on price-sensitive generics and shifting toward specialty and branded products.

Emerging Markets

Sales from Emerging Markets reached US$325 million, up 10.9% YoY, driven by strong performance in branded generics and specialty launches across key regions such as Latin America, Asia, and CIS countries.
Sun Pharma continues to expand its footprint in fast-growing emerging markets, supported by new product registrations and focused marketing efforts.

Rest of the World (RoW)

The RoW segment recorded US$234 million in revenue, showing a strong 17.7% YoY growth.
This growth was supported by consistent demand from Europe and other regulated markets, as well as increased adoption of Sun Pharma’s specialty portfolio.

Active Pharmaceutical Ingredients (API)

The API business reported external sales of ₹4,299 million, reflecting a 19.5% decline, mainly due to lower off-take from external customers. However, APIs continue to play a vital role in strengthening Sun Pharma’s vertical integration and cost competitiveness.

Innovation and Research Focus

Sun Pharma remains committed to developing Innovative Medicines, which accounted for 20.2% of total consolidated global sales in Q2 FY26.
Global sales from innovative products reached US$333 million, marking a 16.4% YoY growth.

The company’s clinical pipeline includes six novel entities, underscoring its growing focus on specialty and innovation-driven portfolios. As of September 2025, Sun Pharma has 117 ANDAs pending approval with the USFDA, having filed four new ANDAs and received five approvals during the quarter.

Management Commentary

Mr. Dilip Shanghvi, Managing Director of Sun Pharma, expressed satisfaction with the results, stating:

“Our focus on differentiated and innovative products continues to yield results. The U.S. business achieved a key milestone as innovative medicines outpaced generics. Growth in India, Emerging Markets, and RoW demonstrates the strength of our diversified business model.”

He further added that the company remains committed to enhancing shareholder value through sustainable growth, continuous R&D investments, and expanding global market reach.

Strategic Outlook

Sun Pharma aims to strengthen its global leadership in specialty and branded formulations through:

Expansion of innovative product pipeline in dermatology, oncology, and ophthalmology.
Increased investments in AI-based drug discovery and precision medicine.
Continued focus on manufacturing excellence and cost optimization.
Enhancing its presence in high-growth international markets with patient-centric solutions.

The company’s balanced mix of branded, specialty, and generic portfolios, combined with a strong R&D foundation, positions it well for sustainable growth in FY26 and beyond.

Investor and Market Insight

Following the announcement, analysts expect Sun Pharma to maintain steady earnings momentum backed by:

Healthy growth in the domestic market,
Rising contribution from specialty and innovative medicines,
Strategic product launches across global markets, and
Strong free cash flow supporting dividend payouts and R&D investment.

Sun Pharma continues to be one of the most trusted pharma stocks in India, favored by investors for its stable fundamentals and forward-looking growth strategy.

Conclusion

The Q2 FY26 performance underscores Sun Pharma’s strength as a global pharmaceutical powerhouse, combining scale, innovation, and strategic execution. With consistent R&D investments and expanding international presence, the company is well-positioned to drive future growth in both developed and emerging markets.

Source: Sun Pharma Press Release – Q2 FY26 Financial Results (PDF)